Podcast appearances and mentions of Michael Wong

Why does the universe produce ever more elaborate forms, from atoms and minerals to cells, organisms, brains, technology, and civilization? The familiar laws of physics can explain much of what happens in nature, but Robert Hazen and Michael Wong argue that something important has been missing: a law describing how evolving systems generate and select new forms over time. Michael Shermer speaks with Hazen and Wong about their proposed law of increasing functional information, the central idea behind their new book Time's Second Arrow. They discuss entropy and the second law of thermodynamics, the origin of life, the Cambrian explosion, emergence and complexity, Stephen Jay Gould and evolutionary contingency, whether evolution has a direction, and why the same basic process of variation and selection may apply far beyond biology.  Shermer also presses them on what evidence could falsify their theory, whether AI could evolve far faster than biological organisms, and the biggest question of all: Does any of this imply that the universe has a purpose? Robert M. Hazen, a geoscientist at the Carnegie Institution for Science, is the author of Symphony in C, among other titles. Michael L. Wong is a planetary scientist and astrobiologist at the Carnegie Institution for Science.

This week the Seattle City Council banned so-called junk fees for renters. Orcas were spotted in Salmon Bay, looking for a seal snack. And 60 cats were rescued from a boat in Tacoma. Asian Verified creator Michael Wong and Simply Seattle’s Danny Ball are here to break down the week. We can only make Seattle Now because listeners support us. Tap here to make a gift and keep Seattle Now in your feed. Got questions about local news or story ideas to share? We want to hear from you! Email us at seattlenow@kuow.org, leave us a voicemail at (206) 616-6746 or leave us feedback online.See omnystudio.com/listener for privacy information.

Burnout doesn’t always look like breaking down. For many men, it looks like continuing to function, going to work, supporting others, staying productive while quietly feeling exhausted, irritable, and disconnected. In this episode, Dr Shami explores the early signs of burnout that are often overlooked, and why recognising them early can make all the difference. This conversation offers a deeper understanding of how burnout develops, not just mentally, but physically, through the nervous system, hormones, and lifestyle patterns. If you’ve been feeling “off” but can’t quite explain why, this episode will help you connect the dots. Connect with Dr Michael Wong at www.mintclinic.com.au Disclaimer: The content in the podcast is not intended to constitute or be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your health care provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have heard on the podcast. Useful links: www.mintclinic.com.auSee omnystudio.com/listener for privacy information.

This week… Thousands of Seattle residents are lining up to volunteer during the World Cup. An iconic local karaoke spot is re-opening its doors. And why does Lumen Field just say "Field" right now? Simply Seattle’s Danny Ball and Asian Verified founder Michael Wong are here to break down the week. And make sure to join us this Saturday for a live taping of Seattle Now where Patricia Murphy will interview King County Executive Girmay Zahilay at the Cascade PBS Ideas Festival. Get tickets here. We can only make Seattle Now because listeners support us. Tap here to make a gift and keep Seattle Now in your feed. Got questions about local news or story ideas to share? We want to hear from you! Email us at seattlenow@kuow.org, leave us a voicemail at (206) 616-6746 or leave us feedback online.See omnystudio.com/listener for privacy information.

Please join my mailing list here

This week… The Seattle Supersonics are dangerously close to a comeback. Mahjong is becoming a favorite social activity for Seattle's young people. And Washington state is making a stuffed marmot the face of a new anti-littering campaign. UW Marketing Professor Jeff Shulman and Asianverified creator Michael Wong are here to break down the week. Read Michael’s piece on mahjong here. We can only make Seattle Now because listeners support us. Tap here to make a gift and keep Seattle Now in your feed. Got questions about local news or story ideas to share? We want to hear from you! Email us at seattlenow@kuow.org, leave us a voicemail at (206) 616-6746 or leave us feedback online.See omnystudio.com/listener for privacy information.

First, Michael Wong and Robert Hazen propose a new scientific theory that suggests complexity — from life to technology — emerges through a universal evolutionary process. Their new book is Time's Second Arrow: Evolution, Order, and a New Law of Nature. In the second half of the show, physicist Suzie Sheehy will share ideas from her 2023 book The Matter of Everything, which pulls back the curtain on the wild, improbable experiments that actually built our understanding of the physical world — and changed everyday life in the process. Shopify — Start your $1/month trial ➡️ ⁠shopify.com/daily⁠ Notion — Try Custom Agents now ➡️ ⁠notion.com/daily 

Robert M. Hazen is Senior Staff Scientist at the Carnegie Institution's Geophysical Laboratory and Clarence Robinson Professor of Earth Sciences at George Mason University. He received the BS and SM in geology at the MIT, the PhD at Harvard University in Earth science, and was NATO Postdoctoral Fellow at Cambridge University. Michael Wong is an astrobiologist and planetary scientist whose primary scientific interests are planetary atmospheres, habitability, biosignatures, and the emergence of life. He is co-authoring a revised edition of the textbook Astrobiology: A Multidisciplinary Approach. He also hosts a podcast that examines science, technology, and culture through the lens of Star Trek. He is working with Staff Scientist Bob Hazen to assess the network topologies of exoplanet atmospheres for potential biosignatures. Please check out these relevant links: Dr. Robert Hazen (Carnegie Science) Dr. Robert Hazen (George Mason University) Dr. Michael Wong (Carnegie Science) Dr. Michael Wong (Website) Time's Second Arrow: Evolution, Order, and a New Law of Nature Strange New Worlds: A Science & Star Trek Podcast Welcome to Dice in Mind, a podcast hosted by Bradley Browne and Jason Kaufman to explore the intersection of life, games, science, music, philosophy, and creativity through interviews with leading creatives. All are welcome in this space. Royalty-free music "Night Jazz Beats" courtesy of flybirdaudio.

Choose your fighter for the origin of water on Earth! Was it always here or did it come to this planet from somewhere else in space? And, either way, what does this mean for other water worlds in our galaxy? To find out, we talk with Michael Wong, an astrobiologist and planetary scientist at Carnegie Science. He gets into scientists' strongest candidates for the ways water could have come to our planet many, many years ago – including whether it could have been made here. Buckle up: This is a hot debate in astrobiology right now.If you enjoyed this episode, check out our Space Camp series and our episode on whether life started on the ocean floor..Interested in more space science and more unresolved hypotheses about how the universe came to be how it is today? Email us your question at shortwave@npr.org.Listen to every episode of Short Wave sponsor-free and support our work at NPR by signing up for Short Wave+ at plus.npr.org/shortwave.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

“Minority voices for all our majority ears...”As another eventful year comes to a close, we recap some favorite voices shared by our many FrieMMds of the Pod in 2025 — so grab a tasty beverage, share with a friend, and enjoy! Featuring the voices of Zohran Mamdani, Vidyut Latay, Varuna Srinivasan, Michael Wong, David Yin, Susie Quesada, Vaibhav, Lisa Angulo Reid, Nicole Ponseca, Suresh Raj, Keith Pedro, Jonathan Hill, Ainsley Waller, Josh Ridenour, Lydia Querian, Brian Velasquez Reid, Bob Gilbreath, Kay Sohini, Ayan Sanyal, Maurice Cherry, Karl Preissner, Stefan K. James, Paresh Jha, Maggie Silver, Loren Appin, Fahad Kawaja, Everette Taylor, Jieun Kim, and Sharon Lee Thony!Special thanks to guest-host Lisa Angulo Reid and producer Alexandre Hirlinger without whom keeping the pod alive in 2025 could not have been possible!

“Minority voices for all our majority ears...”As another eventful year comes to a close, we recap some favorite voices shared by our many FrieMMds of the Pod in 2025 — so grab a tasty beverage, share with a friend, and enjoy! Featuring the voices of Zohran Mamdani, Vidyut Latay, Varuna Srinivasan, Michael Wong, David Yin, Susie Quesada, Vaibhav, Lisa Angulo Reid, Nicole Ponseca, Suresh Raj, Keith Pedro, Jonathan Hill, Ainsley Waller, Josh Ridenour, Lydia Querian, Brian Velasquez Reid, Bob Gilbreath, Kay Sohini, Ayan Sanyal, Maurice Cherry, Karl Preissner, Stefan K. James, Paresh Jha, Maggie Silver, Loren Appin, Fahad Kawaja, Everette Taylor, Jieun Kim, and Sharon Lee Thony!Special thanks to guest-host Lisa Angulo Reid and producer Alexandre Hirlinger — without whom keeping the pod alive in 2025 could not have been possible!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Next stop - the moon! Jeremy Hansen stops by our studio to chat about how he's prepping to be the first Canadian to go to the moon.Plus:Santa's reindeer may be losing their antlers –– and climate change could be the culpritReindeer are the only animal in the deer family where the females also grow antlers, and they typically have a full rack over the wintertime and drop them in June when they give birth. University of Guelph PhD student Allegra Love was monitoring reindeer on Fogo Island in Newfoundland, when she made a surprising discovery that female reindeer are losing and growing their antlers much earlier than usual. This can put more stress on the animal during a crucial part of their pregnancy, and the researchers think this could eventually lead to the reindeer losing their antlers altogether. The work was published in the journal Ecosphere.Pterosaur brains reveal clues about why these mighty fliers took to the skiesFlight has only evolved among vertebrates three times — in bats, birds, and first in pterosaurs. How pterosaurs first took to the skies was always a mystery to scientists, until the discovery of a fossilized 230-million year old pterosaur relative in Brazil. An international team, including Ohio University professor Lawrence Witmer, used an MRI for detailed analysis of the fossilized skull, to pinpoint the miniscule brain changes that happened as the animal developed the capacity to fly. The research was published in the journal Current Biology.Scientists are using AI to find life in 3 billion year old rocksEarth's earliest signs of life are often incredibly difficult to detect. An international team of researchers have developed a new tool that uses AI to find “whispers” of life locked inside ancient rocks. Using this tool, the researchers, including astrobiologist Michael Wong from Carnegie Science, were able to detect fresh chemical evidence of life in rocks that are 3.3 billion years old. This tool can not only be used to explore the origins of life here on Earth, but also on Mars and other planetary bodies. The work was published in the journal PNAS.

This week on the Team Lally Real Estate Radio Show, we interview Gina Hansen, a certified Intuitive Life Designer Coach. Gina shares her powerful story of personal crisis (divorce and cancer) that led her to energy healing. She breaks down her modalities—Emotion Code, Body Code, and Belief Code—explaining how they remove emotional blocks, fix internal "wiring," and rewire the subconscious mind. Gina also delves into the concept of inherited and prenatal emotions that cause generational trauma. She is the author of Soul Rising. We also have Michael Wong of the Laulima Giving Program. He shares that their biggest needs are cash to cover essentials like rent and utilities, and retail gift cards for gas and groceries to help families in the gap who do not qualify for other assistance. In Experts We Trust, meet the Pie Day sponsors: Bradley Maruyama of Allstate Insurance shares that Allstate can offer insurance for single-wall constructed homes, which many other carriers are avoiding, and explains the critical "Moment of Truth" service during a claim. Brian Samson of Cleanscape offers cleaning tips for the holidays, focusing on overlooked areas like the ice machine and cabinet undersides, noting this is a peak time as people want a clean house for the New Year.Who is Gina Hansen?Gina is a powerful example of resilience and renewal. Born in Hilo and raised in Palolo Valley, she began as a young hula dancer, later performing professionally in Japan and Waikīkī. She then spent 28 years as a Hawaii-based flight attendant, traveling throughout Asia and living a life filled with culture and connection. After major life changes in 2020, she embarked on a deep healing journey that led her to her true calling. Today, she's certified in The Emotion Code, Body Code, and Belief Code, and works as an Intuitive Life Designer Coach™ and NLP Master Practitioner—helping people and animals worldwide release emotional blocks and rediscover their balance. Her work now extends into Reinvent Midlife, where she guides women through profound personal transformation.Reinvent Midlife is a healing-centered coaching platform devoted to helping women navigate the emotional, spiritual, and personal transitions that often surface during midlife. Through a blend of intuitive coaching and energy work, the program supports women in releasing old patterns, reconnecting with their inner wisdom, and creating a more aligned and fulfilling next chapter. It serves as a compassionate space for growth, clarity, and renewal—empowering women to rediscover who they are and what they truly want as they step confidently into a more purposeful season of life.To reach Gina Hansen, you may contact her in the following ways:Phone: 808-382-7814Email: reinventmidlife@tm.ginahansen.netWebsite: reinventmidlife.comLinks to social media: https://www.instagram.com/reinventmidlife/ 

This week on the Team Lally Real Estate Radio Show, we interview Gina Hansen, a certified Intuitive Life Designer Coach. Gina shares her powerful story of personal crisis (divorce and cancer) that led her to energy healing. She breaks down her modalities—Emotion Code, Body Code, and Belief Code—explaining how they remove emotional blocks, fix internal "wiring," and rewire the subconscious mind. Gina also delves into the concept of inherited and prenatal emotions that cause generational trauma. She is the author of Soul Rising. We also have Michael Wong of the Laulima Giving Program. He shares that their biggest needs are cash to cover essentials like rent and utilities, and retail gift cards for gas and groceries to help families in the gap who do not qualify for other assistance. In Experts We Trust, meet the Pie Day sponsors: Bradley Maruyama of Allstate Insurance shares that Allstate can offer insurance for single-wall constructed homes, which many other carriers are avoiding, and explains the critical "Moment of Truth" service during a claim. Brian Samson of Cleanscape offers cleaning tips for the holidays, focusing on overlooked areas like the ice machine and cabinet undersides, noting this is a peak time as people want a clean house for the New Year.Who is Gina Hansen?Gina is a powerful example of resilience and renewal. Born in Hilo and raised in Palolo Valley, she began as a young hula dancer, later performing professionally in Japan and Waikīkī. She then spent 28 years as a Hawaii-based flight attendant, traveling throughout Asia and living a life filled with culture and connection. After major life changes in 2020, she embarked on a deep healing journey that led her to her true calling. Today, she's certified in The Emotion Code, Body Code, and Belief Code, and works as an Intuitive Life Designer Coach™ and NLP Master Practitioner—helping people and animals worldwide release emotional blocks and rediscover their balance. Her work now extends into Reinvent Midlife, where she guides women through profound personal transformation.Reinvent Midlife is a healing-centered coaching platform devoted to helping women navigate the emotional, spiritual, and personal transitions that often surface during midlife. Through a blend of intuitive coaching and energy work, the program supports women in releasing old patterns, reconnecting with their inner wisdom, and creating a more aligned and fulfilling next chapter. It serves as a compassionate space for growth, clarity, and renewal—empowering women to rediscover who they are and what they truly want as they step confidently into a more purposeful season of life.To reach Gina Hansen, you may contact her in the following ways:Phone: 808-382-7814Email: reinventmidlife@tm.ginahansen.netWebsite: reinventmidlife.comLinks to social media: https://www.instagram.com/reinventmidlife/ 

Hoy vamos a enfrentar una de las preguntas más grandes quela humanidad se ha hecho: si el universo es tan inmenso, tan lleno de estrellas, planetas y posibilidades… ¿por qué no hemos encontrado aún señales de vida extraterrestre?Vamos a recorrer desde las dimensiones de nuestra galaxia,hasta las teorías más profundas, y a veces inquietantes, sobre por qué todo está tan… silencioso. Incluyendo paradojas, cálculos, y hasta hipótesis recientes de astrobiólogos como Michael Wong y Stuart Bartlett, quienes mezclan sociología, termodinámica y evolución para explicar este misterio.InstagramHandmade Soap Bars - Natural & Artisan Crafted | Jabonera Don GatoCodigo de descuento; CuriosidadY todos mis links aqui abajo.curiosidad científica podcast | Linktree

In this episode, my guest is Michael Wong of Berkshire Hathaway HomeServices Hawaii. Michael shares how Team Wong blends AI, video, and marketing to stay ahead. From dynamic property videos and custom GPTs to prompt libraries, market insights, and brand strategy, Michael shares tools and workflows agents can start using now. Resources Mentioned: Higgs Field – AI video generation for dynamic effects and transitions Runway – AI video editing and creative platform Kling – AI video generation tool Prompts.fun – Michael's prompt library site built with Genspark - https://PromptSmart.fun  HeyGen – AI avatar video tool ElevenLabs – AI voice cloning and generation N8N – Workflow automation platform MidJourney – AI image generation Bio-Visibility Optimizer GPT – GPT for stronger agent bios - https://chatgpt.com/g/g-687e4fde4ac48191aa71be5a671951b5-agent-bio-visibility-optimizer  Guest: Michael Wong Hawaii Home Tours: https://www.instagram.com/hawaiihometours/    Personal Instagram: https://www.instagram.com/mikedubs.hi/ Team Instagram: https://www.instagram.com/teamwonghawaii/  AI News & Tutorials: https://www.instagram.com/mikedubsdigital YouTube: https://www.youtube.com/@TeamWongHawaii  Website: https://teamwonghawaii.com Apps and Tools: https://five-shad-c7b.notion.site/MW-Video-and-AI-Tools-951693ad3770438bbe0729e86dd02220 Host: Rajeev Sajja Rajeev Sajja on Facebook Rajeev Sajja on Instagram Rajeev Sajja on LinkedIn Rajeev Sajja on YouTube Resources: Real Estate AI Flash Podcast Site AI Playbook Join the Instagram Real Estate AI Insiders Channel Join the Real Estate AI Academy waitlist Subscribe to the Real Estate AI Flash Newsletter

Married Trekkie couple, Nicole and Joe, are joined astrobiologist, planetary scientist, photographer, and Star Trek podcaster, Dr. Michael Wong, to gush about Star Trek: Lower Decks! Specifically, we dig into the will they/won't they situationship of D'Vana Tendi & Samanthan Rutherford!***Special shout out to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Steve Combs⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ for the music featured and remixed throughout this episode.Be sure to subscribe to this podcast and follow us over on ⁠⁠Instagram⁠⁠ and ⁠⁠Bluesky ⁠⁠.References:Mike's Podcast: Strange New Worlds: A Science & Star Trek PodcastTime's Second Arrow: Evolution, Order, and a New Law of Nature (Mike's upcoming book)Teaching A.I. to Detect Life: Carnegie Scientist Co-Leads NASA-Funded Effort - Carnegie ScienceSimon Pegg Developed Star Trek Spin-off Movie About Jaylah; Wanted Archer's Dog In ‘Beyond' - TrekMovieWe Asked Star Trek's Eugene Cordero And Noël Wells About Rutherford And Tendi's Relationship In Lower Decks' Final Season. Here's My Deep-Read Into Their Answers - Cinema BlendStar Trek: Lower Decks Creator Mike McMahan Season 4 Changes and Rutherford-Tendi Romance - Comicbook.com

Dr. Michael Wong is an NHFP Sagan Postdoctoral Fellow at Carnegie Science's Earth & Planets Laboratory working with Robert M. Hazen and others. His primary scientific interests are planetary atmospheres, habitability, biosignatures, and the emergence of life. He is also co-authoring a revised edition of the textbook “Astrobiology: A Multidisciplinary Approach” with Professor Jonathan Lunine. His other passions include photography, writing, public speaking, graphic design, and playing a variety of team sports. He hosts a podcast called Strange New Worlds, which examines science, technology, and culture through the lens of Star Trek. Please check out these relevant links: Paper in Nature (behind a paywall) Strange New Worlds Podcast Website Twitter Instagram Pioneer RPG Kickstarter Traveller RPG Welcome to Dice in Mind, a podcast hosted by Bradley Browne and Jason Kaufman to explore the intersection of life, games, science, music, philosophy, and creativity through interviews with leading creatives. All are welcome in this space. Royalty-free music "Night Jazz Beats" courtesy of flybirdaudio.

In this episode of the Mr. Beacon Podcast, Sze Wong—Co-Founder of Zenith Venture Studio—shares his journey from startup failures to building a venture studio that offers more than just funding. Learn how Sze helps non-technical founders turn deep industry knowledge into successful businesses, why boring problems are big opportunities, and how hands-on support beats traditional VC models. A must-listen for entrepreneurs, investors, and innovators alike.Sze's Top 3 Favorite Songs:“Unknown” (Listen on the podcast to try and guess what song this is)“I Believe” by Shin Seung Hun: https://www.youtube.com/watch?v=eNBnPvsufvk“Tong Hua” by Michael Wong: https://www.youtube.com/watch?v=IBTmypxD2mUMister Beacon is hosted by Steve Statler, CEO of AmbAI Inc. — creators of AmbientGPT, the AI assistant that connects people to places, products and the brands behind them. For brands AmbientGPT represents a way to go beyond optimizing your business with AI to securing a place in the new AI purchasing paradigm.Our sponsor Identiv's https://www.identiv.com IoT solutions create digital identities for physical objects, enhancing global connectivity for businesses, people, and the planet. We are also proud to be sponsored by Blecon http://www.blecon.net. Blecon enables physical products to communicate with cloud applications using Bluetooth Low Energy. Hosted on Acast. See acast.com/privacy for more information.

Dr. Michael Wong is an NHFP Sagan Postdoctoral Fellow at Carnegie Science's Earth & Planets Laboratory working with Robert M. Hazen and others. My primary scientific interests are planetary atmospheres, habitability, biosignatures, and the emergence of life. I am also co-authoring a revised edition of the textbook Astrobiology: A Multidisciplinary Approach with Professor Jonathan Lunine. My other passions include photography, writing, public speaking, graphic design, and playing a variety of team sports. I host a podcast called Strange New Worlds, which examines science, technology, and culture through the lens of Star Trek. Please check out these links from the episode: Strange New Worlds Website Twitter Instagram Boldly Go! Welcome to Dice in Mind, a podcast hosted by Bradley Browne and Jason Kaufman to explore the intersection of life, games, science, music, philosophy, and creativity through interviews with leading creatives. All are welcome in this space. Royalty-free music "Night Jazz Beats" courtesy of flybirdaudio.

This week on the Team Lally Real Estate Radio Show, we interview Michael Wong. Michael shares the heart and mission behind Laulima. He talks about how the program helps families in the gap—those who don't qualify for government support—and how donors, local businesses, and community partners keep the mission alive. Michael also speaks on their goals for 2025 and how Laulima continues supporting those in need even during the “off-season” of giving.We also have our Expert We Trust. Duke Kimhan of Hawaii Pacific Property Management shares how clarity from homeowners makes managing rentals much smoother. He talks about critical questions they ask on property walkthroughs, common maintenance issues, and how proactive property managers protect your investment.Who is Michael Wong?Michael Wong, our featured guest, was born in Kona and raised on Oʻahu. With a background as an educator, coach, and advertising professional, Michael brings a deep-rooted passion for serving Hawaiʻi's communities. Now, as the Business Development Specialist for the Laulima Giving Program, he channels his diverse experience into making a lasting impact across the islands—supporting keiki, kūpuna, and families through heartfelt initiatives.The Laulima Giving Program is a nonprofit dedicated to helping Hawaiʻi residents in need who may not qualify for traditional assistance. With programs like Back2School drives, Adopt a Family, and the Laulima Telethon, Laulima works year-round to bring hope and practical support to those facing hardship. Their mission is simple yet powerful: to uplift and empower local families by connecting them with the resources and compassion they deserve.To reach Michael Wong, you may contact him in the following ways:Phone: (808) 979-5283Email: laulima@koka.orgWebsite: LaulimaGivingProgram.org

This week on the Team Lally Real Estate Radio Show, we interview Michael Wong. Michael shares the heart and mission behind Laulima. He talks about how the program helps families in the gap—those who don't qualify for government support—and how donors, local businesses, and community partners keep the mission alive. Michael also speaks on their goals for 2025 and how Laulima continues supporting those in need even during the “off-season” of giving.We also have our Expert We Trust. Duke Kimhan of Hawaii Pacific Property Management shares how clarity from homeowners makes managing rentals much smoother. He talks about critical questions they ask on property walkthroughs, common maintenance issues, and how proactive property managers protect your investment.Who is Michael Wong?Michael Wong, our featured guest, was born in Kona and raised on Oʻahu. With a background as an educator, coach, and advertising professional, Michael brings a deep-rooted passion for serving Hawaiʻi's communities. Now, as the Business Development Specialist for the Laulima Giving Program, he channels his diverse experience into making a lasting impact across the islands—supporting keiki, kūpuna, and families through heartfelt initiatives.The Laulima Giving Program is a nonprofit dedicated to helping Hawaiʻi residents in need who may not qualify for traditional assistance. With programs like Back2School drives, Adopt a Family, and the Laulima Telethon, Laulima works year-round to bring hope and practical support to those facing hardship. Their mission is simple yet powerful: to uplift and empower local families by connecting them with the resources and compassion they deserve.To reach Michael Wong, you may contact him in the following ways:Phone: (808) 979-5283Email: laulima@koka.orgWebsite: LaulimaGivingProgram.org

“Just because your parents wanted the best for you in one way doesn't mean that you rebelling doesn't mean you still can't give back to them by living a good life.” Michael Wong is basically a cultural anthropologist for Asian America. A Seattle-based commentator, Michael's best known for Asian Verified on Instagram + TikTok, and also writes a monthly column for The Stranger, a Seattle newspaper. This is the first of many conversation with Filipino entrepreneurs GUEST-hosted by new FrieMMd of the Pod, past guest, and Filipina entrepreneur Lisa Angulo Reid.  LEARN MORE instagram.com/asianverified thestranger.com/collections/79782549/asian-verified GUEST HOST (Lisa Reid): https://dearflor.com Learn more about your ad choices. Visit megaphone.fm/adchoices

“Just because your parents wanted the best for you in one way doesn't mean that you rebelling doesn't mean you still can't give back to them by living a good life.”Michael Wong is basically a cultural anthropologist for Asian America. A Seattle-based commentator, Michael's best known for Asian Verified on Instagram + TikTok, and also writes a monthly column for The Stranger, a Seattle newspaper. This is the first of many conversation with Filipino entrepreneurs GUEST-hosted by new FrieMMd of the Pod, past guest, and Filipina entrepreneur Lisa Angulo Reid. LEARN MORE instagram.com/asianverified thestranger.com/collections/79782549/asian-verified GUEST HOST (Lisa Reid): https://dearflor.com Learn more about your ad choices. Visit megaphone.fm/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textIn the latest episode of the award-winning podcast Inside Medical Malpractice, host Chris Rokosh continues to examine leaders in the world of patient safety with a riveting interview with Michael Wong, JD. Listen to the powerful story behind Michael's transformation from a successful defense attorney to a leading patient safety advocate. Driven by a promise made to the grieving mother of a young woman who died from opioid-induced respiratory depression while using a Patient Controlled Analgesia (PCA) pump in the hospital, Michael founded the Physician-Patient Alliance for Health and Safety. Tune in as Michael reveals the groundbreaking initiatives PPAHS is spearheading, including the development of checklists and standards for PCA's, DVT's, sepsis and mechanical ventilation care. He passionately discusses the critical need for practical ‘right now' solutions, marketing and cross-disciplinary collaboration to enhance patient safety.  His is clear about this: the need for a future where we work together to fix problems to make sure they don't happen again. Don't miss this inspiring episode that sheds light on Michael's relentless efforts to prevent medical errors and safeguard lives. And find out how you can help out at PPAHS.org.

(via ChatGPT) Humans and Belief in Magic https://chatgpt.com/share/67644975-22c0-8006-af08-9bab51dd1cad People prefer AI-generated poems to Shakespeare and Dickinson http://newscientist.com/article/2456291-people-prefer-ai-generated-poems-to-shakespeare-and-dickinson Michael Wong on Information, Function, and the Origin of Life https://pca.st/xwovbpsy o incrível trabalho do meu xará Renê de Paula: https://www.instagram.com/renedepaula_photography canal do radinho no whatsapp!https://whatsapp.com/channel/0029VaDRCiu9xVJl8belu51Z meu perfil no Threads: https://www.threads.net/@renedepaulajr meu perfil no BlueSky https://bsky.app/profile/renedepaula.bsky.social meu mastodon: ... Read more The post boas festas, raríssimes! muito obrigado! appeared first on radinho de pilha.

Living organisms seem exquisitely organized and complex, with features clearly adapted to serving certain functions needed to survive and procreate. Natural selection provides a compelling explanation for why that is so. But is there a bigger picture, a more general framework that explains the origin and evolution of functions and complexity in a world governed by uncaring laws of physics? I talk with planetary scientist and astrobiologist Michael Wong about how we can define what "functions" are and the role they play in the evolution of the universe.Support Mindscape on Patreon.Blog post with transcript: https://www.preposterousuniverse.com/podcast/2024/12/16/299-michael-wong-on-information-function-and-the-origin-of-life/Michael Wong received his Ph.D. in planetary science from Caltech. He is currently a Sagan Postdoctoral Fellow at the Carnegie Institution for Scienceʼs Earth & Planets Laboratory. He is in the process of co-authoring two books: A Missing Law: Evolution, Information, and the Inevitability of Cosmic Complexity with Robert M. Hazen, and a revised edition of Astrobiology: A Multidisciplinary Approach with Jonathan Lunine.Web siteCarnegie web pageStrange New Worlds podcastWong et al. (2023), "On the Roles of Function and Selection in Evolving Systems."Wong and Prabhu (2023), "Cells as the First Data Scientists."See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week on the Team Lally Real Estate Radio Show, we interview Michael Wong of the Laulima Giving Program. Michael discusses how his organization provides vital assistance to those in need and who don't qualify for government help. He shares how they adopt families, highlights a recent success story, and provides details on their upcoming events. We also learn how we can support their efforts and make a real difference in the lives of struggling families.We also have our Experts We Trust with their Tip of the Week. Duke Kimhan of Hawaii Pacific Property Management, explains why hiring a property manager is essential for investment property owners. He covers the importance of having an on-island representative and how a skilled property manager can make your life easier, protect your investment, and maximize its value. Dan Polimino from the Big Island shares a personal reflection on his recent trip with his son. He talks about the importance of being present and living in the moment, especially in our fast-paced lives. As a realtor, he also touches on managing the stress of helping clients with their real estate needs and why now is still a great time to buy a home.Who is Michael Wong?Michael was born in  Kona and raised on Oahu. He has had a diverse career as an educator, coach, and advertising professional before joining the Laulima Giving Program.The Laulima Giving Program is a community initiative by Keiki O Ka Aina Family Learning Centers. Through events like Back2School drives, Adopt a Family campaigns, and the Laulima Telethon with KHON2, they help support keiki, kupuna, and families in need across Hawaii. The essence of Laulima is to bring together many hands to lighten a heavy load. Their  mission depends on the kindness and generosity of companies and individuals in the community.To reach Michael, you may contact him in the following ways:Phone: (808) 221-5281Email: Michael.wong@KOKA.orgWebsite: https://laulimagivingprogram.org/

This week on the Team Lally Real Estate Radio Show, we interview Michael Wong of the Laulima Giving Program. Michael discusses how his organization provides vital assistance to those in need and who don't qualify for government help. He shares how they adopt families, highlights a recent success story, and provides details on their upcoming events. We also learn how we can support their efforts and make a real difference in the lives of struggling families.We also have our Experts We Trust with their Tip of the Week. Duke Kimhan of Hawaii Pacific Property Management, explains why hiring a property manager is essential for investment property owners. He covers the importance of having an on-island representative and how a skilled property manager can make your life easier, protect your investment, and maximize its value. Dan Polimino from the Big Island shares a personal reflection on his recent trip with his son. He talks about the importance of being present and living in the moment, especially in our fast-paced lives. As a realtor, he also touches on managing the stress of helping clients with their real estate needs and why now is still a great time to buy a home.Who is Michael Wong?Michael was born in  Kona and raised on Oahu. He has had a diverse career as an educator, coach, and advertising professional before joining the Laulima Giving Program.The Laulima Giving Program is a community initiative by Keiki O Ka Aina Family Learning Centers. Through events like Back2School drives, Adopt a Family campaigns, and the Laulima Telethon with KHON2, they help support keiki, kupuna, and families in need across Hawaii. The essence of Laulima is to bring together many hands to lighten a heavy load. Their  mission depends on the kindness and generosity of companies and individuals in the community.To reach Michael, you may contact him in the following ways:Phone: (808) 221-5281Email: Michael.wong@KOKA.orgWebsite: https://laulimagivingprogram.org/

Michael Wong is an author, speaker and meditation teacher who is internationally recognized for his work in the wellness community. His expertise brings together an integrative approach that combines evidence based breath-work, meditation insights and the advocacy of deep rest states. Michael is the Founder of Just Breathe, an education-based training organization and mindfulness app dedicated to helping people to breathe better, manage stress through meditation, and regulate the nervous systems. His podcast THE QUIET LIFE shares in-depth conversations with some of the world's leading psychologists, neuroscientists and thought leaders.This episode is proudly sponsored by:YETI, who's all about helping you embrace a life lived fully and actively, supported by gear that never lets you down. Head to https://www.yeti.com/ to start living every moment to its fullest!Seed®, a microbiome science company creating novel applications of bacteria like the DS-01® to support our gut and digestive health, designed to keep things moving. Head to Seed.com/EVERYBODY and use code 25EVERYBODY to get 25% off your first month of DS-01®..

Session 9 ‘Challenges and Solutions for Early Recognition and Treatment of Sepsis' from the 2024 WSC Spotlight. Featuring Patrick de Marie Katoto, Wiltrud Abels, Glenn Hernandez Poblete, Flavia Machado, Mark Ansermino, Michael Wong, and Eleanor Nwadinobi as your moderator.

Dr. Diwakar Davar and Dr. Jason Luke discuss advances in the neoadjuvant immunotherapy space that were presented at the 2024 ASCO Annual Meeting, including promising outcomes in high-risk melanoma from the NADINA trial, as well as other new treatment options for patients with advanced cancers.    TRANSCRIPT Dr. Diwakar Davar: Hello and welcome to the ASCO Daily News Podcast. I'm your guest host, Dr. Diwakar Davar, and I am an associate professor of medicine and the clinical director of the Melanoma Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. I am delighted to have my colleague and friend Dr. Jason Luke on the podcast today to discuss key late-breaking abstracts and advances in immunotherapy that were presented at the 2024 ASCO Annual Meeting. Dr. Luke is an associate professor of medicine, the associate director of clinical research, and the director of the Cancer Immunotherapeutic Center at the University of Pittsburgh Hillman Cancer Center.   You will find our full disclosures in the transcript of this episode.  Jason, it's always a pleasure to hear your insights on the key trials in these spaces and to have you back as a guest on this podcast that highlights some of the work, especially advances, that were just presented. Dr. Jason Luke: Well, thanks very much for the invitation. I always love joining the podcast. Dr. Diwakar Davar: We'll start very quickly by talking about some advances and really interesting things that happened both in the context of melanoma but also in immunotherapy in general. And we'll start with what I think was certainly one highlight for me, which was LBA2, the late-breaking abstract on the NADINA trial. It was featured in the Plenary Session, and in this abstract, Dr. Christian Blank and colleagues reported on the results of this phase 3 trial of neoadjuvant ipi-nivo. This is the flipped dose of ipi1/nivo3 versus adjuvant nivolumab in PD-1 naive, macroscopic, resectable, high-risk stage 3 melanoma.  By way of background, neoadjuvant immunotherapy for those listening is an area of increasing interest for drug developers and development for both approved and novel agents. Neoadjuvant immunotherapy has been studied with multiple approved agents, including PD-1 monotherapy, PD-1 LAG-3, PD-1 CTLA-4, T-VEC, as well as investigational agents and multiple randomized and non-randomized studies. The benchmark pathologic response rates with these agents range from 17% PCR with PD-1 monotherapy, 45% to 55% PCR with PD-1 CTLA-4 combination therapy, and slightly higher 57% PCR with PD-1 LAG-3 has recently reported by Dr. Rodabe Amaria from MD Anderson. However, as we embark on phase 3 comparisons for various neoadjuvant compared to adjuvant immunotherapy trials and combinations, we're increasingly moving towards event-free survival as the primary endpoint for neoadjuvant versus adjuvant studies. And this was most recently studied in the context of SWOG S1801, a study that was led by Dr. Sapna Patel.  So, Jason, before we start on NADINA, can you briefly summarize the SWOG S1801 trial and the event-free survival statistic reported by Dr. Patel and her colleagues? Dr. Jason Luke: Well, absolutely. And these data were reported at ESMO about two years ago and then in the New England Journal last year. The S1801 study answered a very simple question: What would happen if you took three of the doses of standard adjuvant therapy with pembrolizumab and moved them prior to surgery? And on a high level, the study is as simple as that. And many of us were somewhat skeptical of this trial design because we thought that just moving the doses earlier may not actually have a major impact.  In the study, you alluded to the event-free survival statistic, and that alludes to what was considered an event. And so, without reading all of it, there were several different aspects that were included in terms of time, based on the date of randomization until the first of a series of events, such as disease progression, toxicity from treatment, if the patient was unable to go to surgery or had surgical complications, or if they had delay in starting the adjuvant therapy due to toxicity, and obviously, recurrence of melanoma or death from any cause. In that context, merely moving the 3 doses of pembrolizumab to the neoadjuvant setting saw an improvement in this two-year event free survival to 72% for the neoadjuvant therapy compared to 49% for the adjuvant therapy. That was quite an outstanding change. And again, noting the power of neoadjuvant treatment, really dictating the impact of anti PD-1, again, just with 3 doses moving from adjuvant into the neoadjuvant setting, and I think all of us were somewhat surprised to see that magnitude of a benefit. But it set up the current study very well, where we now look at combination therapy. Dr. Diwakar Davar: So let's move on to the phase 3 NADINA trial. Do you want to perhaps discuss the study design, particularly focusing on the EFS primary endpoint and maybe also touching on the different schedules? So, SWOG S1801 was a neoadjuvant study of 3 cycles of pembrolizumab and how did that compare and contrast to the neoadjuvant combination that was studied in NADINA? Dr. Jason Luke: Well, as you alluded to, NADINA investigated the regimen of nivolumab plus ipilimumab and compared that against adjuvant therapy with nivolumab alone. So, in the study, as you alluded, the dose and schedule of the two drugs used was nivolumab at 3 milligrams per kilogram, and ipilimumab with 1 milligram per kilogram. That was based on a series of signal finding and safety studies that had been previously done by the same group of authors identifying that as the optimal treatment regimen. And it's worth noting that's slightly different than the labeled indication that's generally used for those same drugs for metastatic melanoma, albeit that the NCCN also endorses this schedule. So, in the trial, 423 patients were randomized, 1:1 to receive either neoadjuvant therapy with those 2 doses of nivolumab plus ipilimumab as compared with standard adjuvant therapy with nivolumab following surgery.   Now, one interesting tweak was that there was an adaptive nature to the study, meaning that patients had a fiducial placed at the index lymph node, and after the neoadjuvant therapy in that arm, that lymph node was removed. And if the patient had a major pathological response, they did not go on to receive the adjuvant portion of the treatment. So it was adaptive because those patients who did very well to the neoadjuvant did not require the adjuvant portion. And in those patients who did not achieve a major pathological response, they could go on to have the adjuvant therapy. And that also included the BRAF therapy for those whose tumors were BRAF mutants.  It's also worth pointing out that the definition of event free survival was slightly different than in the S1801 study that was alluded to just a second ago. And here, EFS was defined from the date of randomization until progression due to melanoma or due to treatment. So that's slightly different than the definition in the S1801 trial. So, a somewhat complicated study, but I really applaud the authors because I think this study does mirror what we would likely be doing in actual clinical practice.  Dr. Diwakar Davar: So, just to briefly summarize the efficacy, and then to get your comments on this, the path response, the PCR rate was 47%. The major pathologic response rate, which is the proportion of patients with between 0% to 1/10% of residual viable tumors, was about 12%. And for a major pathologic response rate of 0% to 10% of 59%. And then the rest of the patients had either pathologic partial response, which was 10% to 50%, or pathologic non response or 50% or greater residual viable tumor, all assessed using central pathology grades. The one year RFS was 95% in the FDR patient population versus 76% in the pathologic partial response patient population, 57% in the pathologic non response patient population. So how do you view these results? Can you context the FDR rates and the EFS rates from NADINA relative to nivo-rela and also potentially SWOG 1801? Dr. Jason Luke: Well, I think these are very exciting results. I think that for those of us that have been following the field closely, they're actually not especially surprising because they mirror several studies that have come before them. When we put them in context with other studies, we see that these rates of major pathological response are consistent with what we've seen in phase 2 studies. They're relatively similar. Or I should say that the results from nivolumab and relatlimab, which was also pursued in a phase 2 study of somewhat similar design, are somewhat similar to this. So, combination immunotherapy does look to deliver a higher major pathological response than pembrolizumab alone, as was known in S1801. Which of course, the caveat being is these are cross control comparisons that we need to be careful about. So I think all of these are active regimens, and I think adding a second agent does appear to enhance the major pathologic response rates. When we look at the event free survival, we see something similar, which is that numerically it looks to be that combination immunotherapy delivers a higher event free survival rate. And that looks to be rather meaningful given the difference in the hazard ratios that were observed between these various studies. And here in the NADINA study, we see that 0.3 hazard ratio for EFS is just extremely impressive.  So the abstract then, from ourselves, out of these specific studies, what does this mean more broadly in the real world, where patients exist and the rest of the landscape for clinical trials? I think we can't take enough time to stop for a second and just think about what a revolution we've come forward in with immune checkpoint blockade and melanoma. When I started my career, now, more than 15 years ago, melanoma was the cancer that made cancer bad. And now here we say, in the highest risk of perioperative patients, we can deliver 2 doses of nivolumab and ipilimumab, and essentially half of the patients then don't need to go on, and more than half the patients don't need to go on to have a full surgery and don't need adjuvant therapy. And from what we could tell of a very, very low risk of every heavy recurrence of melanoma. Of course, there's the other half of patients where we still need to do better, but these are just fantastic results and I think highly meaningful for patients.   In the context of ongoing clinical trials, another abstract that was presented during the meeting was the update to the individualized neoantigen therapy, or V940 with pembrolizumab or against pembrolizumab alone. That's the KEYNOTE-942 study. In that study, they presented updated data at two and a half years for relapse free survival, noting a 75% rate without relapse. So those results are also highly intriguing. And these are in a similar population of very high risk patients. And so I think most of us believe that neoadjuvant therapy with this study in NADINA is now confirmed as the priority approach for patients who present with high-risk stage 3 disease. So that would be bulky disease picked up on a scan or palpable in a clinic. I think essentially all of us now believe patients should get preoperative immunotherapy. We can debate which approach to take, and it may vary by an individual patient's ability to tolerate toxicity, because, of course, multi agent immunotherapy does have increased toxicity relative to anti PD-1 alone. But we'll have to wait now for the full phase 3 results from the V940 individualized neoantigen therapy. And if those come forward, that will be an extremely attractive approach to think about for patients who did not achieve a major pathological response to neoadjuvant therapy, as well as of course to the other populations of patients with melanoma where we otherwise currently give adjuvant therapy stage 2B all the way through stage 4 resected. It's an amazing time to think about perioperative therapy in melanoma. Dr. Diwakar Davar: So this is clearly outstanding data, outstanding news. Congratulations to the investigators for really doing what is an investigative initiated trial conducted across multiple continents with a huge sample size. So this clearly appears to be, at this point in time at least, a de facto standard. But is this going to be FDA-approved, guideline-approved, or is it possible in your mind? Dr. Jason Luke: Well, that's an interesting question. This study was not designed with the intent to necessarily try to register this treatment regimen with the FDA. One would have to take a step back and say, with how powerful these data appear, it sort of seemed like it would be too bad if that doesn't happen. But all the same, I think the community and those of us who participate in guideline recommendations are fully supportive of this. So, I think we will see this move into compendium listings that support insurance approval, I think, very, very quickly. So, whether or not this actually becomes formally FDA approved or is in the guidelines, I think this should become the standard approach that is considered for patients, again presenting with high-risk stage 3 disease.  Dr. Diwakar Davar: Fantastic. So now we're going to go in and talk about a slightly different drug, but also from the melanoma context, and that is the safety and efficacy of RP1 with nivolumab in the context of patients with melanoma who are PD-1 failures. So, this is Abstract 9517. And in this abstract, our academic colleagues essentially talked about these data, and we'll start by describing what RP1 is. RP1 essentially is a HSV-1 based oncolytic immunotherapy. And RP1 expresses GM-CSF as well as a fusogenic protein, GALV-GP-R-. And in this abstract, Dr. Michael Wong from MD Anderson and colleagues are reporting the results of IGNYTE, which is a phase I trial of intratumoral RP1 co-administered with systemic nivolumab in patients with advanced metastatic treatment refractory cutaneous melanoma. And the data presented in this abstract represents data from a registration directed, abbreviated as RD, registration directed cohort of RP1 plus nivolumab in PD-1 refractory melanoma. So, let's start with the description of the cohort.  Dr. Jason Luke: Right. So, in this study, there were a total of 156 patients who were presented, and that included an initial safety and dose finding group of 16, as well as the RD cohort, as you noted, of 140 patients. And it's important to point out that this was a cohort that was selected for a very strict definition of progression on anti PD-1, or a combination immunotherapy as their immediately prior treatment. So, all of the patients in the cohort had exposure to anti PD-1, and 46% of them had anti PD-1 plus anti CTLA4, nivolumab and ipilimumab as their immediately prior therapy. This was also a group of relatively high-risk patients when one considers stage. So, within the stage 4 population, the entry here included 51% who had stage M1B, C, and D melanoma. And that is worth pointing out because this is an injectable therapy. So, trials like this in the past have tended to be biased towards earlier stage, unresectable or metastatic melanoma, meaning stage 3B, 3C, 3D and then stage 4m1a. Again, to emphasize the point here, these were pretreated patients who had a strict definition of anti PD-1 resistance, and over half of them, in fact, had high-risk visceral metastatic disease.  In that context, it's very interesting to observe that the overall response rate was described in the total population, as 31%, and that included 12% who achieved complete response. And so, again, to make sure it's clear, we're talking about a treatment where the oncolytic virus is injected into one or multiple sites of recurrent disease, and then the patients administer nivolumab as per standard. And so, I think these data are quite intriguing. Again, such a high- risk population and their maturity now, with a follow-up of over a year, I think, makes this look to be a very interesting treatment option.  Dr. Diwakar Davar: I guess on that topic of mature follow-up, it probably would be important for us to inform our audience that the top line data for the primary analysis was actually just released, I think, earlier today, and wherein the central confirmed objective response rate was 34% by modified RECIST and 33% by RECIST, clearly indicating that these responses, as you noted, very treatment refractory patient population, these responses were clearly very durable. So, you mentioned that there were responses seen in uninjected visceral lesions, responses seen in both PD-1 and PD-1 CTLA-4 refractory patients. Can you talk a little bit about the response rate in these high-risk subgroups, the uninjected visceral lesions, the patients who had both combination checkpoint and epidural refractory response rate by primary PD-1 resistance.  Dr. Jason Luke: Sure. You know, I think, again, to emphasize this point in the study, we saw that there were responses in the non-injected lesions, and I think it's really important to emphasize that. Some have referred to this as a putative abscopal like effect, similar to what is described in radiation. But it implies that local treatment with the oncolytic virus is triggering a systemic immune response. In the higher risk patient population, we'll note that whereas the overall response rate in PD-1 refractory patients was 34%, in the combination of PD-1 and CTLA-4 refractory patients, the response rate was 26%. So, [this is] still very good. And when we looked at that split by stage, as I alluded to before, in the population of patients that had, what you might call earlier unresectable diseases, so 3B through 4A, the response rate was 38%, and in the stage 4 M1b through M1d, it was 25%. So slightly lower, but still very good. And that would be as expected, because, of course, the patients with visceral metastatic disease have more advanced disease, but those response rates look quite good. Again, looking at the combination refractory population as well as the more high-risk disease. Dr. Diwakar Davar: So, clearly, these are very promising data and exciting times for multiple investigators in the field and the company, Replimune, as well. So, what are the next steps? I believe that a registration trial is planned, essentially, looking at this with the goal of trying to get this combination registered. Can you tell us a little bit about IGNYTE-3, the trial design, the control arm, and what you foresee this trial doing over the next couple of years?  Dr. Jason Luke: So, as this agent has been maturing, it's worth pointing out that the company that makes this molecule, called RP1, but I guess now we'll have to get used to this name vusolimogene oderparepvec as the actual scientific term, they have been having ongoing discussions with the FDA, and there is the potential that this agent could come forward on an accelerated path prior to the results being released from a phase 3 trial. That being said, the phase 3 confirmatory study, which is called the IGNYTE-3 study, is in the process of being launched now. And that's a study investigating this molecule in combination with nivolumab, as was alluded to earlier, and a randomized phase 3 design, where that combination is compared with a physician's choice, essentially a chemotherapy-based option.   In that study, it will be 400 patients with stage 3B through stage 4; patients will have progressed on anti PD-1, either as a combination or in sequence, and then come on the study to be randomized to either vusolimogene oderparepvec plus nivolumab versus that physician's choice. And the physician's choice includes chemotherapy agents, but also nivolumab plus relatlimab as another option, or an anti PD-1 monotherapy, if that's deemed to be a reasonable option by the treating investigator. And the primary endpoint of that study is overall survival. And unfortunately, in this highly refractory patient population, that's something that may not take long to identify with key secondary endpoints of progression free survival, as well as overall response rate. I'm quite enthusiastic about this study, given these data, which have now been centrally confirmed as you alluded to before. I think this is a very exciting area of investigation and really crossing my fingers that this may be perhaps the first locally administered therapy which does appear to have a systemic impact that can hold up in phase 3. Dr. Diwakar Davar: Very, very, very exciting results. And I guess it's worthwhile pointing out that this company also has got, I think, multiple studies planned with both RP1 and cutaneous squamous cell carcinoma in a solid organ transplant patient population where single agent activity has already been reported by Dr. Migden at prior meetings, as well as a novel trial of potentially RP2 metastatic uveal melanoma. So we'll now pivot to Abstract 6014. So, 6014 is a drug by a company known as Merus. Essentially, it's a very novel agent. Merus essentially is a company that is specialized in making bicyclics and tricyclics. And these are not bicycles or tricycles, but rather drugs that essentially are bispecific antibodies. And Merus essentially has come up with petosemtamab. I think we're going to have to figure out better names for all of these drugs at some point. But petosemtamab, or MCLA-158, essentially is a bicyclic, targeting both EGFR as well as LGR-5. So EGR-5, of course, is a known oncogenic driver in multiple tumor types, squamous, including non small cell lung cancer, cutaneous squamous cell carcinoma, but also head and neck squamous cell carcinoma. And LGR-5 essentially is leucine-rich repeat-containing G-protein coupled receptor 5, but it's a receptor in cancer stem cells and certainly highly expressed in head neck squam. And MCLA-158, or petosemtamab is a IgG one bispecific with ADCC-activity because of IgG1 backbone co-targeting EGFR and LGR5. Merus had earlier results that evaluated petosemtamab monotherapy. They defined the RP2D and second- and third-line head and neck blastoma patients with a respectable response rate of 37% investigator-assessed ORR with six months median DoR, and this was published by Ezra Cohen about a year or so ago.  In this abstract, Dr. Fayette and colleagues report on the results of the MCLA-158-CL01 trial, which is a trial of pembrolizumab plus petosemtamab in one front line head and neck squamous cell population. So maybe let's start with the description of the cohort. And it is a small trial, but we'll be able, I think, to dig into a little bit about why this might be exciting. Dr. Jason Luke: Yes. So, as alluded to, it's not the biggest trial as yet, but there were 26 patients with anti PD-1 treatment naive head and neck squamous cell carcinoma. And all the patients in the study did receive, as you alluded to, pembrolizumab plus petosemtamab. Based on the label for pembrolizumab, all the patients in this study were PDL-1 positive. So that's one point that it's worth pointing out to make sure that that's understood. This is the population of patients who would be expected to benefit from pembrolizumab in the first place. Now, in the abstract, they reported out only 10 response evaluable patients, but they updated that in the actual slides of presentation at the meeting. So among 24 patients that were alluded to, 67% were described as having had a response, although some of those were yet to be confirmed responses. And when it was evaluated by PDL-1 status, there didn't seem to be a clear enrichment of response in the PD-1 positive more than 20% group, as compared to the 1-19% group. That isn't especially surprising because that was a trend that one would see, presumably with pembrolizumab alone. But overall, I think these data are pretty exciting in terms of a preliminary study. Dr. Diwakar Davar: You know, you mentioned that the objective response rate was high, almost 60-something%. The prognosis of these patients is generally poor. The OS is typically thought of as between 6-15 months. And based on KEYNOTE-048, which was led by Dr. Burtness and colleagues, the standard of care in the setting is pembrolizumab +/- platinum based chemotherapy regimens. Allowing for the fact that we only have 10 patients here, how do you think these results stack up against KEYNOTE-048? And you made a very important point earlier, which was, by definition, pembro is on label only for the CPS. So PDL-1 score, at least in head and neck squamous cell carcinoma CPS and not TPS. But in the CPS 1% or greater patient population, where pembro is on label, how do these results stack up against the KEYNOTE-048 results. Dr. Jason Luke: Right. KEYNOTE-048 is considered the seminal study that dictates frontline treatment in head and neck cancer. And before we dive into this too far, we do want to acknowledge that here we're comparing 26 patients versus a phase 3 trial. So, we're not trying to get too far ahead of ourselves, but this is just a preliminary comparison. But in KEYNOTE-048, as you alluded to, two regimens were superior to chemotherapy. One was the pembrolizumab monotherapy, as well as pembrolizumab plus chemotherapy. So again, the study overall survival, of course, was much higher, the PDL-1 positive subgroup, which is what dictated the unlabeled use of this. But response to pembro monotherapy in that population of patients is still modest. We're talking about upwards of 20-30%. So, if you compare that to, again, preliminary evidence here from this trial of only 24 patients, that response rate of 60% seems extremely high. And so even if that were to come down somewhat in a larger data series of patients, that still looks to be quite promising as a treatment regimen, that might eventually even be chemotherapy sparing for this population of patients. I think this raises a lot of eyebrows that perhaps this dual targeting approach, EGFR and LDR-5, may bring something really important to the field that evolves it. Dr. Diwakar Davar: So, what are the next steps for petosemtamab? You mentioned that the activity was interesting. Are we going to see a larger trial? Any thoughts on where things are going to go?  Dr. Jason Luke: Well, based on the phase 2 data of petosemtamab alone, even without pembrolizumab, the molecule had already been given fast track designation by FDA, which means allowing for greater communication between the drug sponsor in the FDA and designing a seminal study design. One would assume that this trial will be rapidly expanded quite greatly, perhaps to 100 or 200 patients, to try to flush out what the real response rate is in a more meaningful number of patients. But I think these data will probably also trigger the design and probably near-term evaluation or expedited acceleration of a phase III clinical trial design that would potentially validate this against the current standard of care. So, I'm pretty excited. I think we'll see a lot more about this agent in the relatively near future. Dr. Diwakar Davar: So, finally, we'll pivot to the last abstract that we're going to talk about, which is Abstract 2504. It's a relatively interesting target, CCR8 monoclonal antibody. But this is the efficacy and safety of LM-108, and LM-108 is an anti CCR8 monoclonal antibody that is being developed by LaNova Medicine. And the results that are described, actually a pool set of results of combinations of LM-108 with anti PD-1, two separate anti PD-1, in patients with gastric cancer, mostly done ex-U.S., which is interesting because of this patient population, and it's a pool result of several, 3 phase 1 and 2 studies.  LM-108 is an Fc-optimized anti CCR8 monoclonal antibody that selectively depletes tumor infiltrating Tregs. The abstract reported a pooled analysis of three phase 1, 2 trials with 3 different NCT numbers that all evaluated the efficacy of LM-108 and anti PD-1 in patients with gastric cancer. So, let's start with the description of the cohort. Maybe, Jason, you can tell us a little bit about before you start, as you describe the cohort, sort of what we know, editorially speaking, about the difficulty with which Tregs depletion has been tried and obviously failed up until now in the tumor microenvironment. Dr. Jason Luke: Right. I think that's a really interesting comment. And so, for decades, in fact, targeting regulatory T-cell to alleviate immune exclusion in the tumor microenvironment has been of interest in immuno-oncology. And in preclinical mouse models, it seems quite clear that such an approach can deliver therapeutic efficacy. However, by contrast, in human clinical trials, various different Treg depleting strategies have been attempted, and there's really little to no evidence that depleting Tregs from human tumors actually can deliver therapeutic responses. And by that we're referring to CD-25 antibodies. The drug ipilimumab, the CTLA-4 antibody, was punitively described as a Tregs depleter preclinically, but that doesn't seem to be the case in patients. And so, in that background, this is quite an eye raiser that an anti CCR8 antibody could be driving this effect. Now, before we talk about the results of this trial, I will point out, however, that given the Fc-optimization, it's entirely possible that the Tregs are being depleted by this mechanism, but that more could also be going on. Because Fc gamma RII binding by this antibody that could be nonspecific also has the potential to trigger immune responses in the tumor microenvironment, probably mediated by myeloid cells. So I think more to come on this. If this turns out to be the first meaningful Tregs depletor that leads to therapeutic efficacy, that would be very interesting. But it's also possible this drug could have multiple mechanisms.  So, having said all of that, in the clinical trial, which was a pooled analysis, like you mentioned, of LM-108 in combination with anti PD-1 of a couple different flavors, there were 48 patients treated either with LM-108, with pembrolizumab, or with toripalimab, which is another anti PD-1 antibody. On the drug combination was, generally speaking, pretty well tolerated, noting grade 3 treatment related adverse events in the range of 38%, which is somewhat expected given combination immunotherapy. We talked about nivolumab and ipilimumab before, which, of course, gives even higher rates of immune-related adverse events, with the most common toxicities being anemia, lipase elevations, rash, ALC decrease; albeit, quite manageable. Dr. Diwakar Davar: So, what about the objective response rate? Can you contextualize the efficacy? And as you do that, maybe we'll think about what you'd expect in the context of, say, gastric cancer, especially in patients who've never really had a prior checkpoint inhibitor before. What do you think about the ORR? What do you think about the relative efficacy of this combination? Dr. Jason Luke: Well, so, in the study, they described overall response rate in the 36 patients as 36% and described immediate progression for survival of about 6.5 months. And so that was among patients who were treatment naive. And in second-line patients, they actually described an even higher response rate, although it was only 11 patients, but they're at 64%. And so, I think those data look to be somewhat interesting. When I was actually scrutinizing the actual data presented, it was of some interest to note that the quality of responses seemed to be about as good on the lower dose of LM-108, so 3 milligrams per kilogram as compared to 10 milligrams per kilogram. I think there's definitely more to learn here to try to optimize the dose and to fully understand what the overall efficacy of this treatment combination would be.  I would emphasize that in this disease, I think novel treatment strategies are certainly warranted. While anti PD-1 with chemotherapy has moved the needle in terms of standard of care treatment, it's really only a minor subset of patients who derive durable long-term benefit like we normally associate with immune checkpoint blockade. I think these are preliminary data. They're very intriguing.   You alluded to earlier that this population of patients was an Asian data set, and it is well known that the efficacy of chemotherapy and immunotherapy does appear to be somewhat enhanced in Asian populations, and that goes to distributions of metastasis and tumor microenvironment effects, etc. Very difficult to try to tease any of that out in this abstract, other than to look at these data and suggest that this is pretty interesting, both from a novel therapeutic approach, we talked about the Tregs consideration, but also straight up on the efficacy because I think if these data could hold up in a larger number of patients, and particularly in a western population of patients, I think it would be very intriguing. Dr. Diwakar Davar: Certainly, ASCO 2024 had a lot of interesting data, including data from targeted agents, the LAURA trial, ADCs. But just focusing on the immune therapy subset, we certainly saw a lot of great advances in patients who were treated with neoadjuvant as well as relapse refractory disease in the context of RP1 and then a couple of newer agents such as this petosemtamab as well as LM-108. And of course, we cannot forget to highlight the extended DMFS data from the pembro vaccine study from KEYNOTE-942.  Jason, as always, thank you for taking a little bit of time out of your extremely busy schedule to come and give us insights as to how these agents are impacting the landscape. We really value your input and so thank you very much.  Dr. Jason Luke: Thank you for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for your time today. You will find the links to all the abstracts that we discussed in the transcript of this episode. And finally, if you value the insights that you hear on this podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. So, thank you.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow today's speakers:   Dr. Diwakar Davar   @diwakardavar   Dr. Jason Luke   @jasonlukemd      Follow ASCO on social media:    @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn      Disclosures:       Dr. Diwakar Davar:     Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences    Consulting or Advisory Role: Instil Bio, Vedanta Biosciences    Consulting or Advisory Role (Immediate family member): Shionogi    Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences    Research Funding (Inst.): Zucero Therapeutics    Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy       Dr. Jason Luke:    Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX    Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine    Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure    Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)    Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

(Previously published exclusively on the website, this episode is now available in the podcast feed). Wong or Wrong is over. Bonus content isn't as we take a look at In The Line Of Duty 4 with Michael Wong alongside the daredevil and asskicking duo Cynthia Khan and Donnie Yen and First Option from 1996 which […]

(Previously published exclusively on the website, this episode is now available in the podcast feed). Wong or Wrong is over. Bonus content isn’t as we take a look at In The Line Of Duty 4 with Michael Wong alongside the daredevil and asskicking duo Cynthia Khan and Donnie Yen and First Option from 1996 which […]

In this episode I talk with Michael Wong and Collin Creach from Outbuild. TOPICS COVERED: Why Outbuild choose to focus on construction scheduling, How to get buy-in on a construction schedule, What differentiates Outbuild from the competition, the importance of investing in the front end on planning/scheduling, building construction projects digitally before building them physically, how to build a simple solution to a complex problem in a powerful way, and the future / what's to come in our industry/Outbuild. SHOUT OUTS/MENTIONS: Elon Musk, Albert Einstein, Adam Hoots, Construction Brothers, Get Construction Talking, Primavera, Procore --- Send in a voice message: https://podcasters.spotify.com/pod/show/sethyoufree/message

The sci-fi film Dune: Part Two is out in theaters now. The movie takes place on the harsh desert planet, Arrakis, where water is scarce and giant, killer sandworms lurk just beneath the surface. But what do planetary scientists and biologists think about the science of these worms, Arrakis and our other favorite sci-fi planets? Today on the show, Regina G. Barber talks to biologist (and Star Trek consultant!) Mohamed Noor and planetary scientist Michael Wong about Dune, habitable planets and how to make fantasy seem more realistic. Want more of the science behind your favorite fictional worlds? Email us at shortwave@npr.org. Listen to Short Wave on Spotify, Apple Podcasts and Google Podcasts. Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

The Museum's Creativity Series continues with a conversation on the importance of connection, collaboration, and community. Through a grant from LEGO, called the LEGO Playful Learning Museum Network, institutions across the country were tasked with creating a community of practice that focused on playful learning Joining us today are three representatives from LEGO's community of practice who connected over a shared interest in Tinkering Inventive Playsets, Nick Villagra from the Connecticut Science Center, Michael Wong from the Exploratorium, and Brendan Takenaga from Boston Children's Museum. Tune in to learn about how a community of practice operates, where creativity exists in our work, the power of inspiration, half-baked ideas, open communication between peers, and more! Learn more about this partnership on the Exploratorium Blog. Or connect with our guests by emailing Nick at nvillagra@ctsciencecenter.org, Michael at mwong@exploratorium.edu, or Brendan at Takenaga@bostonchildrensmuseum.org.

We welcome Michael Wong, paranormal investigator to the show this week. Michael has taken his love for history and the paranormal and created PN Paranormal. On his channel he investigates haunted locations and explores the history behind these hauntings. Michael shares with us his creepy encounters in an abandoned asylum, hospitals an old haunted prison and an experience with a booty touching spirit you won't wanna miss. Catch him on his YouTube channel. https://youtube.com/@p.nparanormal?si=WuASkVuNYGbI9igx --- Support this podcast: https://podcasters.spotify.com/pod/show/raphael-gonzalez2/support

Welcome!

Continuing our Pride Month 2023 special with queer entrepreneur and LGBTQ advocate Kayla Wong. Born and raised in Hong Kong, many would have come across Kayla as the daughter of actor Michael Wong and supermodel Janet Ma. But after living the majority of her formative years in the limelight, Kayla made a name for herself as an outspoken LGBTQ advocate in Hong Kong. She joins us to talk about how paparazzi played a part in her coming out experience, being out and proud in the social media age, and what we can do to advance LGBTQ+ acceptance in Asia given the cultural nuances. Follow Kayla on Instagram: https://instagram.com/kaylaiw ------------------------------------------------------- Stay Connected with Proudly Asian: Website - ⁠https://proudly-asian.com⁠ Instagram - ⁠https://instagram.com/proudly.asian⁠ Youtube - ⁠https://www.youtube.com/@proudlyasianpodcast Send us a voice message - ⁠https://anchor.fm/proudlyasian/message⁠ Support us - https://ko-fi.com/proudlyasian Email us - ⁠proudlyasianpodcast@gmail.com

Dr. Michael Wong is a Carnegie Postdoctoral Fellow at the Carnegie Institution for Science's Earth & Planets Laboratory working with Robert M. Hazen, Shaunna M. Morrison, Peter Gao, and others. His primary scientific interests are planetary atmospheres, habitability, biosignatures, and the emergence of life. He is also co-authoring a revised edition of the textbook Astrobiology: A Multidisciplinary Approach with Professor Jonathan Lunine. Dr. Wong's other passions include photography, writing, public speaking, graphic design, and playing a variety of team sports. He hosts a podcast called Strange New Worlds, which examines science, technology, and culture through the lens of Star Trek. Please check out these links from the episode: Strange New Worlds Website Twitter Instagram Boldly Go! Welcome to Dice in Mind, a weekly/biweekly podcast in which we explore the meaning of life through the lens of RPGs!  In each episode, we will consider everyday stuff like science, religion, philosophy, and economics…through the lens of a specific roleplaying game and its dice mechanic. If you like what you hear, consider buying us a cup of coffee or becoming a patron.  You can also join the conversation by following us on Facebook. Music by Kevin McCloud courtesy of Creative Commons by Attribution 3.0 license (https://www.youtube.com/c/kmmusic/featured).

Friends, colleagues, and Crime Family--what do you get when a serial rapist isn't put away with hard time? You get two senseless and infuriating murders (at least--maybe more) of Swedish women, who each had their whole lives left to live. Bailey will bring you the stories of Engla Högland and Pernilla Hellegren, who both deserved better, but who were stolen from their lives by the same disturbed man.Beth is in the palate cleanser seat, and is telling you about Doctor Michael Wong. This man is not only a life-changing doctor and patient advocate, he was attacked and nearly killed in the Melbourne, Australia hospital where he was a neurosurgeon. Hospital security is only one of the meaningful causes he now champions, as he invents new ways to save lives, both in the operating theater and amongst his healthcare colleagues. So if you came here today looking for stories of true crime that will both make you grateful for your own safety and also celebrate the survivors amongst us, you've come to the right place. This is what we do at the True Crime BnB. Welcome aboard--we're glad you're here. Now, have a seat, grab a glass, and let's get started. Meow. . . . . .If you enjoy our show, please share our episodes on social media--that's the greatest way to help us find new listeners.Another way is to rate and review on Apple Podcasts or GoodPods, or give us a 5-star rating on whatever platform you prefer!https://linktr.ee/TrueCrimeBnB?utm_source=linktree_profile_share<sid=9e8aa538-d3ee-4823-b2e1-cb1625692e7aYou can find us on Instagram, Twitter, or Facebook @TrueCrimeBnBYou can send us an email at TrueCrimeBnBPod@gmail.comAnd lastly, we would love and appreciate any amount of your support at Patreon, here:https://patreon.com/TrueCrimeBnB?utm_medium=clipboard_copy&utm_source=copyLink&utm_campaign=creatorshare_creator

In this episode, you'll learn how social impact and environmental sustainability can work together. We chat with Michael Wong, Environmental Sustainability Manager with Ferguson, and explore everything about GHG emissions as well as how to start and scale an environment and sustainability program in your business.   00:53 - What should we understand about GHG emissions? 3:20 - Is there standard reporting for GHG emissions? 4:23 - What is net-zero, and how is it connected to ESG? 6:35 - How can social impact professionals impact environmental and sustainability efforts in their organization? 9:41 - Successful examples of environmental and sustainability programs   11:07 - How to start a sustainability program at a smaller company?   12:06 - As a social impact pro, how would you start building a sustainability program?   13:36 - How to scale your sustainability programs

Today, I had the incredible privilege of interviewing Michael Wong, who is the Senior Vice President of Global Sales at Digital Turbine. He is responsible for creating the global vision, driving revenue growth, and establishing the go-to-market strategies in 3 regions. These are my top ten takeaways from our conversation1. Active Listening2. Value 3. Having a winning mentality4. Growth Mindset and being receptive to candid feedback5. Understanding the competitive landscape6. Challenger Sales7. Sending Pre-reads8. Being a strategic and tactical leader9. Out-prepping your competition 10. Operational RigorWe discuss interviewing best practices, being super curious, and putting in what's missing. We reflected on the amazing lessons we learned at LinkedIn and how it's stayed with us as we implement those lessons in our careers. Thank you, Mike, for your mentorship. Check out this episode if you are interviewing. This is a great listen for anyone in sales. If you want to ask Mike any questions, feel free to reach out to him on LinkedIn. https://www.linkedin.com/in/michael-wong-91932/

Today, I had the incredible privilege of interviewing Michael Wong, who is the Senior Vice President of Global Sales at Digital Turbine. He is responsible for creating the global vision, driving revenue growth, and establishing the go-to-market strategies in 3 regions. These are my top ten takeaways from our conversation1. Active Listening2. Value 3. Having a winning mentality4. Growth Mindset and being receptive to candid feedback5. Understanding the competitive landscape6. Challenger Sales7. Sending Pre-reads8. Being a strategic and tactical leader9. Out-prepping your competition 10. Operational RigorWe discuss interviewing best practices, being super curious, and putting in what's missing. We reflected on the amazing lessons we learned at LinkedIn and how it's stayed with us as we implement those lessons in our careers. Thank you, Mike, for your mentorship. Check out this episode if you are interviewing. This is a great listen for anyone in sales. If you want to ask Mike any questions, feel free to reach out to him on LinkedIn. https://www.linkedin.com/in/michael-wong-91932/

A true pioneer Camille Vidal, also known as Mindfull Cami, is on a mission to inspire the world to bring mindfulness into the glass showing that Tasty Doesn't have to be Boozy. For her its all about celebrating Epic Nights & Early Mornings for a hangover-free life. Mindfully Cami is a globally recognised bartender and drinks expert turned mindfulness, yoga and Meditation teacher.   Ashley sits down with Cami for a Bizzimumzi chat discussing all the feelings around new news of carrying twins, bringing the boys into the world the best way she could with her partner, Michael Wong, and maintain her thriving business, La Maison.    Learn more about Camille Vidal's buisness La Maison here: https://www.lamaisonwellness.com/   We love hearing from you! Get in touch with any topic suggestions, questions and feedback at:  info.bizzimumzi@gmail.com   Follow Bizzimumzi on Istagram:  https://tinyurl.com/BizzimumziInstagram    

When bodybuilder Richard Bagdonas was diagnosed with cancer at the age of forty-five, he set out to design a new fitness regimen to help him fight that battle. One that would keep his mind and body strong enough to win. After beating stage IV cancer—and then COVID pneumonia—Richard started sharing his workout story and building a dedicated community of FitFAB warriors. 01:31: Just a few years ago, my family and I went to Mexico.  02:56: I sat down in her office, and I said I have cancer. 05:00: I wrote a letter email to Dr. Michael Wong at MD Anderson. 07:14: Were there any side effects from the immunotherapy? 09:15: Did your doctors think you were crazy? 11:19: I started writing the book during the very first month of cancer treatment. 13:25: I was going back and forth to Houston quite often. 15:14: Cancer that was in my body was completely gone.  17:12: When they ran a CT scan, they found a benign tumor behind her left eyeball the size of an eyeball.  19:51: In 2019 I was cured of cancer.  22:22: I had 30% lung capacity at the time. 25:08: When I was at the hospital, I was vegetarian.  26:11: What is one thing you wish you had known at the beginning of your cancer journey? 26:53: If you could only do one thing to improve health care in the U.S., what would it be and why?  28:14: Thriver Rapid Fire Questions.  29:38: Aside from Cancer U, what's one resource you would recommend for cancer patients and caregivers?  Resources Fit For Any BattleRichard on LinkedInRichard on TwitterEmail Richard

“Know yourself, know your enemy, know your ability and know your surroundings.” – Master WongMy guest this episode is Michael Wong, known to the world as Master Wong.  He is the first martial artist to successfully use YouTube as a teaching platform with a reach of almost 3 Million followers.  His high energy and dynamic teaching style along with engaging content has inspired and educated millions of viewers.  He is truly an internet trailblazer.This episode is all about Master Wong's story and his drive to overcome bullying, gangs, and how martial arts has transformed his life.  My key take away is Know Yourself to Know Your Enemy.  We have to develop an awareness and understand our abilities, be able to read our opponents and gage the threats in our surroundings.  This awareness is vital to choosing the correct tactics and strategies in dangerous situations.  We discuss training strategies, teaching methods, and martial arts mindset and philosophy.  Master Wong's stories of overcoming adversity are inspirational, and he lives and breathes what he teaches.

This week's episode is all about cultivating mental fortitude to thrive on your marathon journey. Amy begins by chatting to the founder of Just Breathe and Boys of Yoga, Michael Wong, about the benefits of yoga and how connecting to your breath can help on your running journey. Amy then heads off on a run with Aimee Fuller, a Team GB Olympian snowboarder who will soon be adding the London Marathon to her list of accomplishments. They talk about Aimee's ascent from childhood gymnast to Team GB snowboarder and the mental strength required to hit those kickers.How to find out more about today's experts:Michael Wong, Website: www.justbreatheproject.com Instagram: @michaeljameswongAimee Fuller, Instagram: @aimee_fuller See acast.com/privacy for privacy and opt-out information.

Achieving balance requires discipline, practice, and a realistic framework. Over time, with consistent effort, you will find yourself getting better and better at it until it is second nature. The definition of balance, however, is very personal and different for every individual. It takes time and attention to understand what your version of balance is that makes you feel energetic in the various aspects of your life. Rob explains exactly how he evolved into his current state of balance and now keeps it going with ease. Michael Wong and Alex Comfortes founded Peeka VR to get kids excited about reading again. They use visual technology to immerse children in stories with the goal of igniting their passion for reading and learning. But sitting between two slow moving industries, publishing and education, they want to know how to move fast and disrupt. Justin Kershaw had spoken with Rob in 2020 when he was introduced by Outstanding Foods CEO and Founder, Bill “Billy G” Glaser. Rob couldn't quite see the vision of Sow Strong Food back then. But that didn't stop Justin. He went out and hustled to bring his brand to life, and Rob is incredibly impressed. He wasn't coming on the show looking for a deal with Dyrdek Machine, but you never know what can happen on Build With Rob.  Learn more about this episode.